Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Shares Issued: 2017-2025

Historic Shares Issued for Denali Therapeutics (DNLI) over the last 7 years, with Sep 2025 value amounting to $583,000.

  • Denali Therapeutics' Shares Issued was N/A to $583,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $504.5 million, marking a year-over-year change of. This contributed to the annual value of $499.3 million for FY2024, which is 2701.64% up from last year.
  • Per Denali Therapeutics' latest filing, its Shares Issued stood at $583,000 for Q3 2025, which was down 85.63% from $4.1 million recorded in Q2 2025.
  • Denali Therapeutics' Shares Issued's 5-year high stood at $499.3 million during Q1 2024, with a 5-year trough of $583,000 in Q3 2025.
  • Over the past 3 years, Denali Therapeutics' median Shares Issued value was $3.3 million (recorded in 2023), while the average stood at $65.3 million.
  • Per our database at Business Quant, Denali Therapeutics' Shares Issued surged by 31,025.50% in 2024 and then crashed by 99.88% in 2025.
  • Denali Therapeutics' Shares Issued (Quarterly) stood at $5.2 million in 2021, then soared by 5,418.50% to $285.2 million in 2022, then plummeted by 98.35% to $4.7 million in 2023, then spiked by 31,025.50% to $499.3 million in 2024, then plummeted by 99.88% to $583,000 in 2025.
  • Its last three reported values are $583,000 in Q3 2025, $4.1 million for Q2 2025, and $595,000 during Q1 2025.